Healium Medical

Company Overview

Snapshot

Founded in February 2017, Healium Medical has 11–50 employees and has raised $18.75 million across four funding rounds from three investors. In September 2022, the company secured a grant from EIC Accelerator.

Business overview

Healium Medical is a Health Tech & Life Sciences company focused on developing advanced medical devices for the treatment of atrial fibrillation. The company's core product is the Echomplish platform, a contactless transcatheter ultrasound system designed for circumferential pulmonary vein isolation with real-time lesion monitoring. This system includes customized hardware in a mobile console and procedure software that provides clinical insights on tissue properties and therapy progress. Healium Medical operates within the medical devices sector, targeting healthcare providers with innovative solutions for cardiology and interventional pulmonology.

Strategic signal

In September 2022, Healium Medical entered into a strategic cooperation agreement with Broncus Holding Corporation to integrate Broncus' energy ablation with Healium's ultrasound technology for lung cancer treatment. This collaboration is significant as it aims to create a single real-time tool for targeting, treating, and monitoring ablated tissues, signaling the company's expansion beyond cardiology into interventional pulmonology and demonstrating the versatility and potential of its ultrasound technology in new therapeutic areas.

Company Intelligence Q&A

What is Healium Medical's primary focus?

Healium Medical focuses on the treatment of atrial fibrillation using non-contact transcatheter system technology, developing a miniature transcatheter ultrasound transducer array for contactless circumferential pulmonary vein isolation with real-time lesion monitoring.

What is the Echomplish platform?

The Echomplish platform is Healium Medical's system designed for an intuitive ablation procedure experience. It consists of customized hardware in a standalone mobile console and procedure software that offers clinical insights on tissue properties and therapy progress based on real-time data from the CQure ultrasound ablation catheter.

What strategic partnership did Healium Medical form in September 2022?

In September 2022, Healium Medical entered into a strategic cooperation agreement with Broncus Holding Corporation to integrate Broncus' energy ablation with Healium's ultrasound technology for lung cancer treatment, aiming to create a single real-time tool for targeting, treating, and monitoring ablated tissues.

Did Healium Medical form a joint venture for renal artery denervation?

Yes, in June 2021, Venus Medtech (Hangzhou) Inc. formed a joint venture company called Renaly Ltd. with Healium Medical Ltd. to introduce Healium's renal artery denervation (RDN) innovative system and develop, manufacture, and commercialize RDN products worldwide.